Vanderbilt-Ingram Cancer Center (VICC) — Nashville, Tennessee

Vanderbilt-Ingram Cancer Center (VICC) is a clinical research site located in Nashville, Tennessee, United States 37240.

Crixeo Clinical Trials Trust Score: 73/100 (FAIR). This profile has not yet been claimed by the site owner.

Vanderbilt-Ingram Cancer Center (VICC) has participated in 7 clinical trials with 1 currently active.

Therapeutic areas: Multiple Myeloma, Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma.

Sponsors: European Myeloma Network B.V., Cue Biopharma, Innovis LLC.

Sponsor Feasibility Report

Trust Score: 73/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Vanderbilt-Ingram Cancer Center (VICC)?

Vanderbilt-Ingram Cancer Center (VICC) has a Crixeo Trust Score of 73/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Vanderbilt-Ingram Cancer Center (VICC) conducted?

Vanderbilt-Ingram Cancer Center (VICC) has 7 clinical trials on record, with 1 currently active. Their work covers Multiple Myeloma, Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma.

Is Vanderbilt-Ingram Cancer Center (VICC) accredited by Crixeo Clinical Trials?

Vanderbilt-Ingram Cancer Center (VICC) has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Vanderbilt-Ingram Cancer Center (VICC)?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.